INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 47 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $2,376,000 | -10.2% | 2,666,000 | 0.0% | 0.02% | -11.8% |
| Q1 2019 | $2,645,000 | +7.3% | 2,666,000 | 0.0% | 0.02% | 0.0% |
| Q4 2018 | $2,465,000 | -22.8% | 2,666,000 | -15.8% | 0.02% | -5.6% |
| Q3 2018 | $3,194,000 | +14.7% | 3,166,000 | 0.0% | 0.02% | +12.5% |
| Q2 2018 | $2,784,000 | +8.9% | 3,166,000 | 0.0% | 0.02% | +6.7% |
| Q1 2018 | $2,556,000 | +0.1% | 3,166,000 | 0.0% | 0.02% | 0.0% |
| Q4 2017 | $2,554,000 | -17.3% | 3,166,000 | -20.8% | 0.02% | -16.7% |
| Q3 2017 | $3,090,000 | -20.6% | 4,000,000 | 0.0% | 0.02% | -21.7% |
| Q2 2017 | $3,890,000 | +4.3% | 4,000,000 | 0.0% | 0.02% | +4.5% |
| Q1 2017 | $3,728,000 | +93.1% | 4,000,000 | +84.6% | 0.02% | +100.0% |
| Q4 2016 | $1,931,000 | +15.1% | 2,167,000 | +44.5% | 0.01% | +10.0% |
| Q3 2016 | $1,677,000 | – | 1,500,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Birch Grove Capital LP | 15,003,000 | $13,500,000 | 6.56% |
| PenderFund Capital Management Ltd. | 9,605,000 | $10,735,000 | 2.51% |
| Silver Point Capital L.P. | 38,808,000 | $34,151,000 | 1.87% |
| Benefit Street Partners LLC | 5,045,000 | $4,440,000 | 1.69% |
| Context Capital Management, LLC | 11,279 | $10,168,000 | 0.94% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 57,791,000 | $51,920,000 | 0.92% |
| DeepCurrents Investment Group LLC | 30,292,000 | $27,169,000 | 0.81% |
| Saltoro Capital, LP | 1,800,000 | $1,623,000 | 0.66% |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 20,481,000 | $18,638,000 | 0.52% |
| Kohlberg Kravis Roberts & Co. L.P. | 64,548,000 | $58,191,000 | 0.24% |